| Summary: | Su Liu,1 Xubin Li,2 Yueyang Li,1 Dongying Li,1 Yafei Wang,1 Chen Tian11Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, People’s Republic of China; 2Imaging Department, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, People’s Republic of ChinaAbstract: Multiple myeloma is an incurable clonal B-cell malignancy which may present with neoplastic monoclonal plasma cells in either bone or soft tissues. Central nervous system (CNS) involvement such as dural myeloma or intraparenchymal infiltration, or with diffuse leptomeningeal involvement, is uncommon. Dural involvement of myeloma without parenchymal or leptomeningeal disease is an even rarer occurrence; therefore there are no established treatment guidelines for CNS myelomatosis. Here we reported a refractory MM patient progressed to dura mater involvement after the induction therapy but showed good response to lenalidomide treatment.Keywords: multiple myeloma, dura mater involvement, lenalidomide
|
|---|
